ADC Therapeutics (NYSE:ADCT) Trading Down 1.3%

ADC Therapeutics SA (NYSE:ADCT – Get Rating)’s share price fell 1.3% during trading on Friday . The company traded as low as $2.26 and last traded at $2.28. 228,679 shares were traded during trading, a decline of 61% from the average session volume of 588,899 shares. The stock had previously closed at $2.31.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ADCT shares. Royal Bank of Canada decreased their price target on ADC Therapeutics from $18.00 to $12.00 and set an “outperform” rating on the stock in a research note on Monday, February 13th. Bank of America lowered ADC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Monday, April 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, ADC Therapeutics has an average rating of “Moderate Buy” and an average target price of $10.17.

ADC Therapeutics Stock Down 1.3 %

The company has a debt-to-equity ratio of 2.57, a quick ratio of 4.46 and a current ratio of 4.69. The firm has a market capitalization of $175.13 million, a P/E ratio of -0.90 and a beta of 1.10. The stock has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $3.26.

ADC Therapeutics (NYSE:ADCT – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.19. ADC Therapeutics had a negative return on equity of 229.20% and a negative net margin of 108.86%. The business had revenue of $69.80 million during the quarter, compared to the consensus estimate of $75.53 million. Research analysts forecast that ADC Therapeutics SA will post -2.73 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ADCT. Ameriprise Financial Inc. boosted its position in ADC Therapeutics by 43.5% during the 1st quarter. Ameriprise Financial Inc. now owns 112,906 shares of the company’s stock worth $220,000 after acquiring an additional 34,236 shares during the period. JPMorgan Chase & Co. boosted its position in ADC Therapeutics by 2.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,091,814 shares of the company’s stock worth $6,029,000 after acquiring an additional 87,348 shares during the period. Perceptive Advisors LLC acquired a new position in ADC Therapeutics during the 1st quarter worth $2,917,000. Susquehanna International Group LLP boosted its position in ADC Therapeutics by 86.4% during the 1st quarter. Susquehanna International Group LLP now owns 26,028 shares of the company’s stock worth $51,000 after acquiring an additional 12,065 shares during the period. Finally, Jane Street Group LLC acquired a new position in ADC Therapeutics during the 1st quarter worth $50,000. 75.56% of the stock is currently owned by institutional investors.

ADC Therapeutics Company Profile

(Get Rating)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL).